Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norwegian Pancreatic Cancer Trial
2015-001635-21Phase 3Active
- Sponsor
- Norwegian Gastrointestinal Cancer Group
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of FOLFIRINOX and gemcitabine in pancreatic cancer (PC), sponsored by Norwegian Gastrointestinal Cancer Group. Primary endpoint: Overall survival at 1 year after surgery. Started Jun 2015; status: active.
02
Drugs
FOLFIRINOXgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2015-001635-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001635-21.